drugset / Trial / NCT01074593

Pharmacokinetics and Pharmacodynamics of the Interferon Beta-1a Produced by Laboratorio Quimico Farmaceutico Bergamo Compared to Interferon Beta-1a (Rebif - Merck Serono) in Healthy Subjects

NCT01074593

Phase 1 Completed 20 enrolled Azidus Brasil
RandomizedCrossoverOpen-label

Summary

The primary objective of this study is to compare the pharmacokinetic and pharmacodynamic effect of two commercial preparations of interferon beta-1a (IFN Test: Lab Bergamo and IFN Comparator: Rebif ® - Merck Serono Lab) after single administration (12.000UI) in healthy subjects by modifying the parameters Cmax, Tmax and AUC (pharmacokinetics) and the levels of 2'5' oligoadenylate synthase and beta-2-microglobulin (pharmacodynamics).

Timeline

Start
2011-01
Primary completion
2011-03
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Interferon beta-1a Protein / enzyme biologic 12000 iu

Indications

No indication recorded.